Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
7.45
-0.31 (-3.99%)
Mar 18, 2026, 11:46 AM EDT - Market open
Solid Biosciences Employees
Solid Biosciences had 100 employees as of December 31, 2024. The number of employees increased by 12 or 13.64% compared to the previous year.
Employees
100
Change (1Y)
12
Growth (1Y)
13.64%
Revenue / Employee
n/a
Profits / Employee
-$1,671,350
Market Cap
580.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 100 | 12 | 13.64% |
| Dec 31, 2023 | 88 | 1 | 1.15% |
| Dec 31, 2022 | 87 | -17 | -16.35% |
| Dec 31, 2021 | 104 | 34 | 48.57% |
| Dec 31, 2020 | 70 | -51 | -42.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Replimune Group | 479 |
| MeiraGTx Holdings | 409 |
| Allogene Therapeutics | 229 |
| ADC Therapeutics | 193 |
| Alpha Tau Medical | 125 |
| DBV Technologies | 117 |
| Tectonic Therapeutic | 60 |
SLDB News
- 5 days ago - Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 days ago - Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start - Seeking Alpha
- 6 days ago - Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
- 6 days ago - Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - GlobeNewsWire
- 12 days ago - Solid Biosciences Announces Oversubscribed $240 Million Private Placement - GlobeNewsWire
- 12 days ago - Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewsWire
- 15 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Solid Biosciences Inc. (SLDB) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript - Seeking Alpha